Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534913 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL2775177 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL535710 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL23071637 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL3497513 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL25380441 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL64393 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL73945 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL11277600 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD | |
| SCHEMBL11277597 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024234610-A1 | ELECTROLYTE FOR MAGNESIUM ION BATTERY, PREPARATION METHOD THEREFOR, AND MAGNESIUM ION BATTERY | 清华大学 | 2024-11-21 | — | — | WO | claimed |
| CN-116454388-A | Electrolyte for magnesium ion battery, preparation method of electrolyte and magnesium ion battery | 清华大学 | 2023-07-18 | — | — | CN | claimed |
| CN-103451659-B | Method of inhibiting corrosion in airtight cooling water system | 栗田工业株式会社 | 2016-06-08 | — | — | CN | claimed |
| CN-105087182-A | Circuit substrate cured with solder, a manufacturing method of circuit substrate equipped with electronic part, and cleaning agent composition for fluxing agent | KAO CORP | 2015-11-25 | — | — | CN | claimed |
| CN-101735175-A | Olefin epoxidation method with hydrophobic rhenium ion liquid as catalyst | UNIV LIAONING | 2010-06-16 | — | — | CN | claimed |
| WO-2002003982-A1 | ANTIMYCOTIC PHARMACEUTICAL | INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) | 2002-01-17 | — | — | WO | claimed |
| US-5077355-A | EPOXY RESIN/IMIDAZOLE/POLYPHENOL ADDUCT AS EPOXY CURING AGENT | SOMAR CORPORATION (JP) | 1991-12-31 | — | — | US | claimed |
| EP-0385745-A2 | Powder coating composition | SOMAR CORPORATION (JP) | 1990-09-05 | — | — | EP | claimed |
| US-4339448-A | Imidazole-copper complex compounds and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | claimed |
| US-12410347-B2 | Adhesive composition, and coverlay film and printed circuit board that include the same | DOOSAN CORPORATION (KR) | 2025-09-09 | — | — | US | disclosed |
| CN-119978199-A | Reactive branched isobutylene-based composite cationic salt copolymer, preparation method thereof and antibacterial coating | 中国石油化工股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119978200-A | Curable reactive branched isobutenyl cationic salt copolymer, preparation method, curable epoxy resin composition and water-resistant mildew-proof coating | 中国石油化工股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250034316-A1 | CURABLE COMPOSITION, CURED PRODUCT AND CURING CATALYST FOR BLOCKED ISOCYANATE COMPOUND | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
| WO-2025023309-A1 | COMPOSITION FOR FORMING CURED FILM, ALIGNMENT MATERIAL, AND PHASE-DIFFERENCE MATERIAL | 日産化学株式会社 | 2025-01-30 | — | — | WO | disclosed |
| US-4339448-A | Imidazole-copper complex compounds and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | disclosed |
| US-3991201-A | 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
| US-3991201-A | 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
| US-3991201-A | 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
| US-3932444-A | PLASTICIZERS | E. I. DU PONT DE NEMOURS & CO. (US) | 1976-01-13 | — | — | US | disclosed |
| US-3927017-A | 1-({62 -Aryl-{62 -R-ethyl)imidazoles | JANSSEN PHARMACEUTICA NV | 1975-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034316-A1 | CURABLE COMPOSITION, CURED PRODUCT AND CURING CATALYST FOR BLOCKED ISOCYANATE COMPOUND | C5, KDM2B, KDM6B | TBXAS1 2714/4885TERT 468/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.